These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 32379004)

  • 1. Combination immunotherapy of oncolytic virus nanovesicles and PD-1 blockade effectively enhances therapeutic effects and boosts antitumour immune response.
    Ji W; Li L; Zhou S; Qiu L; Qian Z; Zhang H; Zhao P
    J Drug Target; 2020 Nov; 28(9):982-990. PubMed ID: 32379004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma.
    Vijayakumar G; Palese P; Goff PH
    EBioMedicine; 2019 Nov; 49():96-105. PubMed ID: 31676387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer.
    Sun F; Guo ZS; Gregory AD; Shapiro SD; Xiao G; Qu Z
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma.
    Kiyokawa J; Kawamura Y; Ghouse SM; Acar S; Barçın E; Martínez-Quintanilla J; Martuza RL; Alemany R; Rabkin SD; Shah K; Wakimoto H
    Clin Cancer Res; 2021 Feb; 27(3):889-902. PubMed ID: 33257429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression.
    Nelson A; Gebremeskel S; Lichty BD; Johnston B
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35246474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade.
    Kowalsky SJ; Liu Z; Feist M; Berkey SE; Ma C; Ravindranathan R; Dai E; Roy EJ; Guo ZS; Bartlett DL
    Mol Ther; 2018 Oct; 26(10):2476-2486. PubMed ID: 30064894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy.
    Ilett E; Kottke T; Thompson J; Rajani K; Zaidi S; Evgin L; Coffey M; Ralph C; Diaz R; Pandha H; Harrington K; Selby P; Bram R; Melcher A; Vile R
    Gene Ther; 2017 Jan; 24(1):21-30. PubMed ID: 27779616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade.
    Ju F; Luo Y; Lin C; Jia X; Xu Z; Tian R; Lin Y; Zhao M; Chang Y; Huang X; Li S; Ren W; Qin Y; Yu M; Jia J; Han J; Luo W; Zhang J; Fu G; Ye X; Huang C; Xia N
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
    Rojas JJ; Sampath P; Hou W; Thorne SH
    Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telomerase-specific oncolytic immunotherapy for promoting efficacy of PD-1 blockade in osteosarcoma.
    Mochizuki Y; Tazawa H; Demiya K; Kure M; Kondo H; Komatsubara T; Sugiu K; Hasei J; Yoshida A; Kunisada T; Urata Y; Kagawa S; Ozaki T; Fujiwara T
    Cancer Immunol Immunother; 2021 May; 70(5):1405-1417. PubMed ID: 33151368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced anti-melanoma efficacy through a combination of the armed oncolytic adenovirus ZD55-IL-24 and immune checkpoint blockade in B16-bearing immunocompetent mouse model.
    Hu HJ; Liang X; Li HL; Wang HY; Gu JF; Sun LY; Xiao J; Hu JQ; Ni AM; Liu XY
    Cancer Immunol Immunother; 2021 Dec; 70(12):3541-3555. PubMed ID: 33903973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.
    Hardcastle J; Mills L; Malo CS; Jin F; Kurokawa C; Geekiyanage H; Schroeder M; Sarkaria J; Johnson AJ; Galanis E
    Neuro Oncol; 2017 Apr; 19(4):493-502. PubMed ID: 27663389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Checkpoint Blockade Plus Oncolytic Virus: A Hot Therapeutic Cancer Strategy.
    Robert C
    Trends Mol Med; 2017 Nov; 23(11):983-985. PubMed ID: 29137714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
    Vijayakumar G; McCroskery S; Palese P
    J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody.
    Kanaya N; Kuroda S; Kakiuchi Y; Kumon K; Tsumura T; Hashimoto M; Morihiro T; Kubota T; Aoyama K; Kikuchi S; Nishizaki M; Kagawa S; Tazawa H; Mizuguchi H; Urata Y; Fujiwara T
    Mol Ther; 2020 Mar; 28(3):794-804. PubMed ID: 31991110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The oncolytic virus VT09X optimizes immune checkpoint therapy in low immunogenic melanoma.
    Zhu W; Lv J; Xie X; Tian C; Liu J; Zhou H; Sun C; Li J; Hu Z; Li X
    Immunol Lett; 2022 Jan; 241():15-22. PubMed ID: 34774916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.
    Ribas A; Dummer R; Puzanov I; VanderWalde A; Andtbacka RHI; Michielin O; Olszanski AJ; Malvehy J; Cebon J; Fernandez E; Kirkwood JM; Gajewski TF; Chen L; Gorski KS; Anderson AA; Diede SJ; Lassman ME; Gansert J; Hodi FS; Long GV
    Cell; 2017 Sep; 170(6):1109-1119.e10. PubMed ID: 28886381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic viruses as engineering platforms for combination immunotherapy.
    Twumasi-Boateng K; Pettigrew JL; Kwok YYE; Bell JC; Nelson BH
    Nat Rev Cancer; 2018 Jul; 18(7):419-432. PubMed ID: 29695749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T-cell receptor signalling.
    Armstrong E; Chiu MKL; Foo S; Appleton L; Nenclares P; Patrikeev A; Mohan N; Mclaughlin M; Bozhanova G; Hoebart J; Roulstone V; Patin E; Pedersen M; Kyula J; Ono M; Errington-Mais F; Bell J; Harrington KJ; Melcher A; Jennings V
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39060020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.